NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis $2.31 -3.02 (-56.66%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About INmune Bio Stock (NASDAQ:INMB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get INmune Bio alerts:Sign Up Key Stats Today's Range$2.00▼$2.3450-Day Range$2.31▼$8.2452-Week Range$1.93▼$11.64Volume32.68 million shsAverage Volume702,458 shsMarket Capitalization$53.08 millionP/E RatioN/ADividend YieldN/APrice Target$22.80Consensus RatingBuy Company OverviewINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Read More… INmune Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreINMB MarketRank™: INmune Bio scored higher than 41% of companies evaluated by MarketBeat, and ranked 710th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingINmune Bio has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageINmune Bio has received no research coverage in the past 90 days.Read more about INmune Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for INmune Bio are expected to grow in the coming year, from ($2.24) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about INmune Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted49.12% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently increased by 17.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted49.12% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 16.8, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently increased by 17.48%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment0.05 News SentimentINmune Bio has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for INmune Bio this week, compared to 3 articles on an average week.Search Interest12 people have searched for INMB on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.MarketBeat Follows5 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders35.70% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.72% of the stock of INmune Bio is held by institutions.Read more about INmune Bio's insider trading history. Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address INMB Stock News HeadlinesINmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 30 at 4:05 PM | globenewswire.comINmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trialJune 30 at 12:56 PM | proactiveinvestors.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.June 30 at 2:00 AM | Crypto 101 Media (Ad)INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage studyJune 30 at 7:36 AM | reuters.comINmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's DiseaseJune 30 at 7:30 AM | globenewswire.comINmune Bio's US$24m Market Cap Fall Books Insider LossesJune 28 at 1:36 PM | finance.yahoo.comINmune Bio Inc. (INMB) Stock Price Today - WSJJune 28 at 3:34 AM | wsj.comINmune Bio Stock Price, Quotes and Forecasts | NASDAQ:INMB - BenzingaJune 28 at 3:34 AM | benzinga.comSee More Headlines INMB Stock Analysis - Frequently Asked Questions How have INMB shares performed this year? INmune Bio's stock was trading at $4.67 at the start of the year. Since then, INMB stock has decreased by 50.5% and is now trading at $2.31. View the best growth stocks for 2025 here. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43). The firm earned $0.05 million during the quarter. Read the conference call transcript. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX). Company Calendar Last Earnings5/08/2025Today6/30/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INMB CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$22.80 High Stock Price Target$30.00 Low Stock Price Target$18.00 Potential Upside/Downside+938.7%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.08 million Net MarginsN/A Pretax Margin-81,592.01% Return on Equity-119.35% Return on Assets-89.37% Debt Debt-to-Equity RatioN/A Current Ratio2.64 Quick Ratio2.64 Sales & Book Value Annual Sales$10 thousand Price / Sales5,044.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book1.51Miscellaneous Outstanding Shares22,980,000Free Float14,779,000Market Cap$50.44 million OptionableOptionable Beta1.55 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:INMB) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.